Therapeutic Asset Ratings
462 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Catch T Cells
Neoplasm
Baylor College of Medicine
P1
C
(36)
Cbp-1018
Neoplasm
Coherent Biopharma (Suzhou) Co., Ltd.
P1
C
(36)
Cbp-1019
Neoplasm
M.D. Anderson Cancer Center
P1
C
(36)
cct303-406
Neoplasm
Shanghai PerHum Therapeutics Co., Ltd.
P1
C
(36)
Cedazuridine
Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P1
C
(36)
cf33-hnis
Neoplasm
Imugene Limited
P1
C
(36)
Cldn6 Car-T
Neoplasm
BioNTech Cell & Gene Therapies GmbH
P1
C
(36)
Cldn6 Urna-Lpx/Cldn6 Modrna-Lpx
Neoplasm
BioNTech Cell & Gene Therapies GmbH
P1
C
(36)
Cpg-Odn
Neoplasm
Second Affiliated Hospital of Guangzhou Medical University
P1
C
(36)
Cusp06
Neoplasm
OnCusp Therapeutics, Inc.
P1
C
(36)
Dfp-14927
Neoplasm
Delta-Fly Pharma, Inc.
P1
C
(36)
dk210
Neoplasm
DEKA Biosciences
P1
C
(36)
dr30206
Neoplasm
Zhejiang Doer Biologics Co., Ltd.
P1
C
(36)
Drug: Ibi3028
Neoplasm
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
P1
C
(36)
ds-1055a
Neoplasm
Daiichi Sankyo
P1
C
(36)
Dxp-106
Neoplasm
Singlomics Biopharmaceuticals Zhuhai Co., Ltd.
P1
C
(36)
Ecp-1014
Neoplasm
Euclises Pharmaceuticals, Inc.
P1
C
(36)
Enoblituzumab
Neoplasm
Masonic Cancer Center, University of Minnesota
P1
C
(36)
es014
Neoplasm
Elpiscience (Suzhou) Biopharma, Ltd.
P1
C
(36)
Etakafusp Alfa
Neoplasm
Asher Biotherapeutics, Inc.
P1
C
(36)
eu103
Neoplasm
Eutilex
P1
C
(36)
exs74539
Neoplasm
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
P1
C
(36)
Fcn-098
Neoplasm
Fochon Pharmaceuticals, Ltd.
P1
C
(36)
ftl001
Neoplasm
Sound Biopharmaceuticals Ltd.
P1
C
(36)
gc203 til
Solid Tumor
Shanghai Juncell Therapeutics
P1
C
(36)
Showing 301 to 325 of 462 assets
Previous
Page 13 of 19
Next